Quantcast

Latest Dainippon Sumitomo Pharma Co. Ltd. Stories

2014-05-21 00:20:51

EPI-743 in phase 2B/3 development for Leigh syndrome MOUNTAIN VIEW, Calif., May 21, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome. EPI-743 is currently in phase 2B development for the treatment of Leigh syndrome. A phase 2B randomized double-blind placebo-controlled trial in children with Leigh syndrome is fully enrolled in the...

2014-03-10 00:21:49

First subject enrolled in pivotal clinical trial MOUNTAIN VIEW, Calif., March 10, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B/3 study entitled, "A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome" to be conducted in conjunction with Dainippon Sumitomo Pharma Co, Ltd. The trial is an open-label study lasting six months. To be eligible for the trial, children must have clinical and radiographic evidence of Leigh...

2014-02-04 23:27:41

MitoAction and UMDF have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon Sumitomo Pharma Co., Ltd. of Japan. (PRWEB) February 04, 2014 The nation’s leading mitochondrial disease patient advocacy organizations have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon Sumitomo Pharma Co., Ltd....

2013-10-14 23:20:31

Reportbuyer.com just published a new market research report: Global Pulmonary Drug Delivery Systems Market 2012-2016. London (PRWEB) October 14, 2013 TechNavio's analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 14.47 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of lung-related or respiratory diseases. The Global Pulmonary Drug Delivery Systems market has also been...

2011-04-07 04:00:00

OSAKA, Japan and NORWOOD, Mass., April 7, 2011 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Boston Biomedical, Inc. ("BBI"), today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada. BBI608 is an orally administered, first-in-class, small molecule anti-cancer drug that targets highly malignant cancer stem cells as well as other...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related